High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia.
BRAF
EGFR
Indonesia
KRAS
Thyroid cancer
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
12 Dec 2022
12 Dec 2022
Historique:
received:
04
05
2022
accepted:
29
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Thyroid cancer incidence has steadily increased in Indonesia. However, data on Kirsten rat sarcoma virus (KRAS) and EGFR mutations in thyroid cancer in Indonesia remain unavailable, except for BRAF-V600E, the most common BRAF gene mutation. This study aimed to analyze KRAS and EGFR mutation profiles in BRAF-V600E negative thyroid cancer samples. BRAF-V600E mutations were found in papillary thyroid carcinomas in 40.3% patients with mean age of 53 years old. In BRAF-V600E-negative samples, 41.3% had KRAS mutations with mean age of 55.5 years old. KRAS mutation was found in 52.6% of follicular carcinomas and 47.4% of papillary thyroid carcinomas. Additionally, 45.7% had EGFR mutations in patients with mean age of 50.5 years old. EGFR mutation was found in 71.4% of papillary thyroid carcinoma and 28.6% of follicular carcinoma. Nearly half of the BRAF-V600E negative thyroid carcinoma samples harbored either KRAS or EGFR mutations. This finding suggests that in BRAF-V600E negative thyroid carcinoma samples, testing for RAS and EGFR mutation may be warranted for further therapeutic consideration.
Identifiants
pubmed: 36510281
doi: 10.1186/s13104-022-06260-4
pii: 10.1186/s13104-022-06260-4
pmc: PMC9743704
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
KRAS protein, human
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
BRAF protein, human
EC 2.7.11.1
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
369Informations de copyright
© 2022. The Author(s).
Références
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
J Clin Endocrinol Metab. 2021 Mar 25;106(4):1129-1138
pubmed: 33382428
Oncologist. 2013;18(8):926-32
pubmed: 23873720
Case Rep Oncol. 2014 Jun 18;7(2):393-400
pubmed: 25076890
Hum Pathol. 2017 Mar;61:164-172
pubmed: 27818286
Am J Surg. 2020 Aug;220(2):334-340
pubmed: 31818425
PLoS One. 2018 Jun 7;13(6):e0198795
pubmed: 29879227
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Transl Lung Cancer Res. 2020 Apr;9(2):325-336
pubmed: 32420072
J Clin Oncol. 2015 Jan 1;33(1):42-50
pubmed: 25332244
J Pathol Transl Med. 2016 May;50(3):197-203
pubmed: 27086595
Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234
pubmed: 33662333
Thyroid. 2012 Jul;22(7):683-9
pubmed: 22650231
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9
pubmed: 18682506
BMC Cancer. 2020 May 1;20(1):368
pubmed: 32357861
Cancers (Basel). 2019 Mar 10;11(3):
pubmed: 30857358
Front Endocrinol (Lausanne). 2020 Mar 13;11:102
pubmed: 32231639
Cancer Cytopathol. 2014 Dec;122(12):873-82
pubmed: 25132659
Anticancer Res. 2013 Nov;33(11):4779-84
pubmed: 24222113
J Surg Oncol. 2015 Aug;112(2):149-54
pubmed: 26175314
Malays J Pathol. 2016 Aug;38(2):141-8
pubmed: 27568671
Cancer Res. 2006 Jul 1;66(13):6521-9
pubmed: 16818623
J Surg Res. 2013 Nov;185(1):217-24
pubmed: 23746767
Langenbecks Arch Surg. 2012 Jun;397(5):809-15
pubmed: 22350610
Clin Cancer Res. 2004 Dec 15;10(24):8594-602
pubmed: 15623643
Cancer Res. 2005 May 15;65(10):4238-45
pubmed: 15899815
J Clin Endocrinol Metab. 2007 Jun;92(6):2264-71
pubmed: 17374713